Understanding C17orf47: A Potential Drug Target and Biomarker

Target Name: Chromosome 17 open reading frame 47

NCBI ID: G284083

Chromosome 17 open reading frame 47

Other Name(s): C17orf47 | Uncharacterized protein C17orf47

Understanding C17orf47: A Potential Drug Target and Biomarker

Chromosome 17 open reading frame 47 (C17orf47) is a gene that has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic makeup and expressed proteins make it an attractive target for researchers to study and potentially develop new treatments.

The C17orf47 gene is located on chromosome 17, one of the 23 pairs of chromosomes found in the human body. It is responsible for encoding a protein, known as C17orf47, which is a key regulator of the cell's barrier function. This protein plays a crucial role in maintaining the integrity of the cell membrane, which is critical for many cellular processes, including cell signaling, transport, and inflammation.

C17orf47 is expressed in many different tissues and cells in the body, including the brain, heart, liver, and blood cells. It is also overexpressed in many diseases, which means that it is produced at higher levels than normal. This overproduction can lead to the formation of aggregates, known as lipid-rich inclusions, in the cells. These aggregates can disrupt the cell's normal functions and contribute to the development of a variety of diseases.

One of the ways in which C17orf47 is linked to disease is its role in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's. These conditions are characterized by the progressive loss of brain cells and the development of aggregates that cause the symptoms. C17orf47 has has been shown to be involved in the formation of these aggregates, which may contribute to the development and progression of these diseases.

C17orf47 is also being studied as a potential drug target for a variety of other conditions, including cancer, autoimmune disorders, and liver disease. For example, studies have shown that C17orf47 is overexpressed in many types of cancer, including breast, lung, and ovarian cancer. This overproduction can lead to the formation of aggregates, which can disrupt the tumor's normal functions and contribute to the development and progression of the disease. Similarly, C17orf47 has also been shown to be involved in the development of autoimmune disorders, such as rheumatoid arthritis and lupus.

In addition to its potential as a drug target, C17orf47 is also being studied as a biomarker for a variety of diseases. For example, studies have shown that C17orf47 is overexpressed in the blood cells of people with many different types of cancer, including breast, lung, and ovarian cancer. This overproduction can be used as a biomarker for the disease, as it is often associated with an increased risk of metastasis. Similarly, C17orf47 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's. The levels of C17orf47 in the brain can be used as a biomarker for these conditions.

Overall, C17orf47 is a gene that is being studied for its potential as a drug target and biomarker for a variety of diseases. Its unique genetic makeup and expressed proteins make it an attractive target for researchers to study and potentially develop new treatments. As research continues to progress, it is likely that the true potential of C17orf47 will be revealed, and it will be exciting to see how this gene contributes to the development of new treatments for a variety of conditions.

Protein Name: Chromosome 17 Open Reading Frame 47

The "Chromosome 17 open reading frame 47 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Chromosome 17 open reading frame 47 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets